Back to Rare Disease
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT01784679

NCT01784679
Completed Not Applicable

Who may be able to join

Who might be able to join this trial:

  • You must be willing and able to give electronic consent for your medical information to be shared with the study organizers.
  • You must have been diagnosed with one of the following conditions: GNEM, HIBM, Quadriceps Sparing Myopathy (QSM), Inclusion Body Myopathy Type 2, distal myopathy with rimmed vacuoles (DMRV), or Nonaka disease.
  • You must be willing and able to follow all of the study's procedures and requirements.
  • You must be willing to have your information included in the GNEM Disease Registry (a database tracking this condition).
  • You must be able to provide genetic test results confirming GNE disease — note that genetic testing will not be done as part of this study, so you would need to provide existing results from your doctor or another source.
  • In the opinion of the study doctor, you are likely to attend scheduled visits and follow study procedures.

Who may not be able to join:

  • For the in-person part of the study (Natural History Component): if you have another illness or condition that the study doctor believes would interfere with your participation or affect your safety, you may not be eligible (confirm with trial site).
  • For the online registry part of the study: there are no reasons that would prevent you from joining this portion.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Trial details

Status
Completed
Phase
Not Applicable
Sponsor
Ultragenyx Pharmaceutical Inc
Registry
clinicaltrials_gov
Start date
5 April 2013
Est. completion
30 November 2017

Where this trial is recruiting

🇧🇬 Bulgaria 🇨🇦 Canada 🇫🇷 France 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Characterize HIBM disease presentation and progression over time using relevant clinical assessments of muscle strength and function.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov